Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors simultaneously. It represents the next evolution beyond dual agonists like tirzepatide, adding glucagon receptor activity to further enhance metabolic effects.
In the Phase 2 trial published in the New England Journal of Medicine, retatrutide produced up to 24.2% body weight loss at the highest dose over 48 weeks — the largest weight reduction ever reported for any anti-obesity medication in a clinical trial. The triple-agonist approach addresses obesity from three distinct hormonal pathways.
The addition of glucagon receptor agonism increases energy expenditure and hepatic lipid oxidation, complementing the appetite-suppressing effects of GIP and GLP-1 activation. This mechanism also showed remarkable effects on liver fat reduction, with some patients achieving complete resolution of fatty liver disease.
Looking for the best vendor deals?
Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.
Compare Vendors